Clinical Trials and Experimental Treatments: What Health Plans Cover

Coverage for experimental treatments and clinical trials is one of the trickiest parts of employee health benefits. In the United States, the default for most employer-sponsored health plans, whether fully insured or self-funded, is to exclude treatments that aren't 'medically necessary' or 'proven' according to established standards of care. But that's changing, thanks to state and federal mandates, legal rulings, and rising specialty-care costs.

Let's split this into two categories: clinical trials (typically cancer-related or FDA-regulated studies) and experimental treatments (unproven therapies, off-label uses, or investigational drugs). The rules differ, and the financial stakes are high for both employers and employees.

How Traditional Health Plans Treat Clinical Trials

For standard group health plans (PPOs, HMOs, self-funded plans), coverage of clinical trial costs used to be limited. The Affordable Care Act (ACA) changed this for most plans. Since 2014, a non-grandfathered group health plan cannot deny a member participation in an approved clinical trial for cancer or another life-threatening condition, and it must cover the member's routine patient costs in that trial. That means the plan covers:

• Routine medical care: doctor visits, lab tests, imaging, hospital stays that would normally be covered if the patient weren't in a trial.
• Standard diagnostic procedures: scans, biopsies, and other tests to monitor the condition.
• Management of side effects: treatment for complications from the trial.

What the plan doesn't have to cover: the investigational drug or device itself, the research team's costs, or data collection. Those are usually paid by the trial sponsor (a pharmaceutical company or the NIH).

Key Exceptions and Limitations

• Self-funded plans: The federal ACA mandate applies to self-funded plans as well as fully insured ones. The exception is a grandfathered plan, one that existed on March 23, 2010 without changes that cut benefits or raised costs; grandfathered plans can still exclude routine trial costs.
• Medicare and Medicaid: Traditional Medicare covers routine costs in approved clinical trials. Medicare Advantage plans may have narrower networks, which can complicate access to a trial site. Medicaid covers routine patient costs in clinical trials, though eligibility rules vary by state.
• State mandates: Most states have laws on the books regarding clinical trial coverage; a 2024 review counts 37 states plus the District of Columbia. State laws reach only fully insured plans, because ERISA preempts state regulation of self-funded plans. Self-funded employers answer to the federal ACA standard instead.

What About 'Experimental' Treatments That Aren't in a Trial?

Here the system is much stricter. Most employer-sponsored plans exclude treatments that are:

• Investigational: not FDA-approved for the condition.
• Off-label: FDA-approved for one condition but used for another without strong evidence.
• Unproven: stem cell injections, hyperbaric oxygen outside protocols, high-dose vitamin C for cancer.

These exclusions exist for a reason: health plans pay for evidence-based care that's proven safe and effective. Cover unproven treatments, and costs skyrocket, underwriting assumptions blow up, and liability risks rise.

When Employers Might Cover Experimental Therapies

Limited scenarios exist where employers voluntarily extend coverage:

1. Compassionate use programs: Some drug manufacturers offer expanded access for patients who've exhausted options. Plans might cover associated medical costs (hospital stays, monitoring) even if the drug is free.
2. Self-funded plan customization: Employers with self-funded plans can add a 'clinical trial rider' or 'specialty drug exception policy' for certain investigational treatments for rare or life-threatening conditions. This is rare and usually reserved for high-wage workforces.
3. State mandates for rare diseases: More states require plans to cover off-label drug use for rare diseases if peer-reviewed evidence supports it. Again, mandates usually only apply to fully insured plans.

Expanded Access and Right to Try: Who Pays

Outside a clinical trial, patients with serious or life-threatening conditions have two federal routes to an investigational drug: the FDA's expanded access program (compassionate use) and the Right to Try Act of 2018. Both let a patient request an unapproved drug, and neither puts the cost on the health plan. Under Right to Try, which applies to drugs that have completed a Phase I trial, the law does not require insurers to pay for the drug or for the office visits and hospital stays tied to its use. Those costs can land on the patient, or the manufacturer may waive the drug's price.

That matters for employers because a Right to Try or expanded access request does not create a new coverage obligation. The investigational drug was never a covered benefit, and the federal laws do not make it one. Plans keep their existing investigational exclusions, and patients keep the right to ask the manufacturer directly. A short policy note explaining that routine care is handled separately from the drug's own cost keeps expectations clear on both sides.

The Role of Appeals and External Review

When a claim for an experimental treatment is denied, employees have the right to appeal. Under ERISA (for employer-sponsored plans), the process includes:

• Internal appeal: The employee or doctor submits extra evidence (medical literature, case studies, expert opinions) to justify the treatment.
• External review: If the internal appeal is denied, many states and federal laws require an independent third-party review. This is often the last chance for coverage, and it can succeed if the evidence is solid.

The burden falls on the patient to show the treatment's likely benefit outweighs risks. Plans want peer-reviewed evidence, not anecdotes.

Strategic Considerations for Employers and HR Leaders

How an employer handles experimental treatments and clinical trials directly impacts trust, retention, and engagement. WellthCare's ecosystem thinking suggests a preventive-first approach can reduce demand for experimental treatments. Employees who keep up with annual scans, lab work, and care plans are less likely to face advanced-stage diseases that need desperate measures. WellthCare, the first Health-to-Wealth Benefit System, guides members toward clinically validated care pathways with a personalized, clinician-reviewed plan of care, reducing the need for last-resort experimental options. But when the need arises, a transparent policy covering clinical trial costs for life-threatening conditions can be a powerful part of an employer's benefits story, especially in industries with high chronic illness or older workers. Conversely, a blanket exclusion can erode trust if employees feel denied hope in a crisis.

Best Practices for Coverage Decisions

• Review your plan document carefully: Make sure it defines 'experimental' and spells out the appeal process. Ambiguity invites lawsuits.
• Educate employees: Many don't realize that routine clinical trial costs are often covered. A quick FAQ or a chat with a nurse concierge (like WellthCare's Wellby AI) clears things up.
• Consider a specialty pharmacy carve-out: For high-cost investigational drugs, a transparent pharmacy solution (like WellthCare Pharmacy™) can cut costs while giving employees access to emerging therapies when appropriate.
• Monitor state and federal changes: The FDA and state legislatures keep expanding access to trials and off-label treatments. Stay informed to keep your plan compliant and competitive.

The Bottom Line

Generally, health benefits don't cover experimental treatments unless part of a qualifying trial or an employer exception. The system is risk-averse for good reason: unproven therapies can be dangerous and unsustainable. But coverage isn't binary. With smart plan design, careful appeals management, and a preventive focus, employers can balance cost and compassion. In an era of rising healthcare costs and employee demands for value, a clear policy on experimental care is good business.